HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis.

AbstractBACKGROUND:
Bisphosphonate and denosumab are widely used for the treatment of osteoporosis and bone metastasis of cancer to prevent excessive bone resorption. Osteonecrosis of the jaw is a serious adverse effect of bisphosphonate or denosumab referred to as bisphosphonate-related osteonecrosis of the jaw (BRONJ) or denosumab-related osteonecrosis of the jaw (DRONJ), respectively. Since bisphosphonate and denosumab inhibit bone resorption by different mechanism, we evaluated whether these drug types result in different histopathological characteristics related to bone resorption.
MATERIALS AND METHODS:
We histopathologically investigated 10 cases of BRONJ, DRONJ, and suppurative osteomyelitis. Paraffin sections prepared from decalcified dissected jaw bones were used for histopathological observation, second harmonic generation imaging, and bone histomorphometry. The samples were also observed by a scanning electron microscope.
RESULTS:
Numerous bone resorption lacunae were observed on the necrotic bone surface in almost all cases of BRONJ; however, such resorption lacunae were limited in DRONJ and suppurative osteomyelitis. Prominent bone resorption lacunae were also confirmed by second harmonic generation imaging and scanning electron microscopy in BRONJ, but not in DRONJ or suppurative osteomyelitis. As determined by bone histomorphometry, the number of bone resorption lacunae and the length of the erosion surface of resorption lacunae were significantly higher in BRONJ group than in the DRONJ and suppurative osteomyelitis groups. These parameters were correlated between the necrotic bones and the vital bones in BRONJ.
CONCLUSIONS:
Persistent bone resorption lacunae on the necrotic bone surface are unique to BRONJ, providing a basis for distinguishing BRONJ from DRONJ and OM in histopathological diagnosis.
AuthorsKazumitsu Aoki, Satoru Matsunaga, Shinichirou Ito, Takahiko Shibahara, Takeshi Nomura, Hideo Matsuzaki, Shinichi Abe, Akira Yamaguchi
JournalJournal of bone and mineral metabolism (J Bone Miner Metab) Vol. 39 Issue 5 Pg. 737-747 (Sep 2021) ISSN: 1435-5604 [Electronic] Japan
PMID33830351 (Publication Type: Journal Article)
Copyright© 2021. The Japanese Society Bone and Mineral Research.
Chemical References
  • Bone Density Conservation Agents
  • Diphosphonates
  • Denosumab
Topics
  • Bisphosphonate-Associated Osteonecrosis of the Jaw (diagnostic imaging)
  • Bone Density Conservation Agents (adverse effects)
  • Bone Neoplasms
  • Bone Resorption
  • Denosumab (adverse effects)
  • Diphosphonates
  • Humans
  • Osteonecrosis (chemically induced, diagnostic imaging)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: